Emergent BioSolutions Q1 revenue falls 30%

Emergent BioSolutions

30/04/2026 21:48

Overview

Medical countermeasures maker's Q1 revenue fell 30% yr/yr

Q1 revenue rose above company guidance and estimates

Company authorized up to $50 mln in share repurchases through March 2027

Outlook

Emergent BioSolutions sees 2026 total revenues of $720 mln to $760 mln

Company raises 2026 adjusted net income forecast to $45 mln-$65 mln from $25 mln-$45 mln

Emergent BioSolutions expects Q2 2026 revenues of $170 mln to $185 mln

Result Drivers

GOVERNMENT ORDER TIMING - Co said lower anthrax and smallpox countermeasure sales were due to timing of government purchases and reduced international demand

NALAXONE SALES MIX - Naloxone revenue declined due to unfavorable price-volume mix in US sales, partially offset by higher Canadian sales and KLOXXADO integration

OTHER PRODUCTS GROWTH - Higher BAT sales in Canada and internationally drove a sharp increase in other product revenue

Company press release: ID:nGNXcgY3dQ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$156.10 mln
$145 mln (2 Analysts)
Q1 Adjusted EPS
$0.21
Q1 EPS
$0.07
Q1 Adjusted Net Income
Beat
$11.90 mln
-$14.80 mln (2 Analysts)
Q1 Net Income
$6.80 mln
Q1 Adjusted EBITDA
Beat
$35.60 mln
$16.80 mln (1 Analyst)
Q1 Gross Margin
41.00%
Q1 Adjusted Gross Margin
52.00%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Emergent BioSolutions Inc is $12.00, about 50.2% above its April 29 closing price of $7.99

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)